Inovio Pharmaceuticals, Inc..
INO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and prevent cancers and infectious diseases. Their SynCon® technology and CELLECTRA® delivery system are central to their approach. The company's pipeline in...Show More
Better Health for All
40
Inovio Pharmaceuticals' entire business is dedicated to developing DNA medicines to treat and prevent cancers and infectious diseases.
1
For instance, INO-3107 for recurrent respiratory papillomatosis showed a 50% complete response at year 2-3 and an 81% reduction in surgical interventions.
2
The company has no products with significant negative health impacts. Its products demonstrate an outstanding safety record; INO-3107 trials reported no treatment-related serious adverse events, with all adverse events being Grade 1 or 2,
3
and the CELLECTRA® 3PSP device has a safe profile over 6,000 administrations.
4
In 2024, the company's R&D expenses were $75.6 million against total revenues of $218,000, representing over 25% of its total operating expenses, which were $112.6 million.
5
This indicates a significant investment in health innovation. The company's focus on developing vaccines for infectious diseases like COVID-19, MERS, Zika, Ebola, and HIV demonstrates a strong emphasis on disease prevention.
6
During the COVID-19 pandemic, Inovio developed a DNA vaccine (INO-4800) and received over $20 million in grants from organizations like the Bill & Melinda Gates Foundation and CEPI to accelerate its development and scale-up, showcasing a structured crisis response.
7
8
Fair Money & Economic Opportunity
0
No evidence available to assess Inovio Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Inovio Pharmaceuticals has an employee rating of 3.3 out of 5 stars on Glassdoor, which translates to an engagement score of 66%.
1
The company's Code of Business Conduct and Ethics, reviewed in May 2025, outlines commitments to equal employment opportunity, prevention of harassment, and a zero-tolerance policy for workplace violence.
2
It also includes whistleblower protection with an anonymous reporting hotline.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Inovio Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Inovio Pharmaceuticals has a formal whistleblower policy, last amended on May 16, 2023, which includes a 24/7 reporting hotline (Convercent) that allows for anonymous reporting and explicitly protects whistleblowers from retaliation.
1
The policy covers accounting, legal, and ethical matters, and outlines investigation procedures.
2
The company also maintains a strong anti-corruption policy, prohibiting bribery, including facilitation payments, to government officials and private citizens, and addresses compliance with the Foreign Corrupt Practices Act (FCPA) and third-party intermediary responsibilities.
3
This policy covers non-compliance with anti-bribery laws.
4
Additionally, the company's Code of Business Conduct and Ethics requires Board of Directors approval and disclosure for waivers concerning executive officers, senior financial officers, or directors, indicating a mechanism for managing potential conflicts of interest.
5
Kind to Animals
-40
Inovio Pharmaceuticals conducts animal testing for its medical products and clinical research, including preclinical animal challenge studies for vaccines and DNA-based monoclonal antibodies.
1
The company has tested its COVID-19 drug candidate on mice and guinea pigs, and plans to test in rabbits and monkeys.
2
Other studies involved mice, ferrets, and non-human primates (cynomolgus and rhesus macaques).
3
One study used 65 cynomolgus macaques.
4
Inovio also plans to test an African Swine Fever vaccine in small and larger animal models, including pigs.
5
The company does not explicitly mention the use of in vitro or computational methods to replace animal testing.
6
Animal experiments are conducted under IACUC-approved protocols in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations.
7
The facilities where this research was conducted are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
8
Inovio's subsidiary VGX Animal Health sold its animal health assets, including an exclusive license for animal applications of its GHRH technology and animal DNA vaccines, to Plumbline Life Sciences, Inc. in 2014.
9
Inovio retains human applications of its GHRH technology
10
and approximately 15% equity ownership in Plumbline.
11
The company has no formal collaborations or minimal engagement with animal welfare stakeholders.
No War, No Weapons
-30
In the second quarter of 2025, the company reported $0 in revenue from arms contracts.
1
However, in 2022, revenue was generated from a U.S. Department of Defense procurement contract for devices and accessories related to a COVID-19 vaccine candidate.
2
The company's CELLECTRA® 3PSP smart device, used to deliver a COVID-19 vaccine, received $71 million from the U.S. Department of Defense in 2020 and $8.1 million in funding from the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium starting in 2019.
3
Additionally, the company's DMAb technology is funded by the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
4
Planet-Friendly Business
0
No specific, concrete data points related to planet-friendly business metrics for Inovio Pharmaceuticals, Inc. (INO.US) were found in the provided articles. Several articles explicitly state that no reports or data are available for the company regarding these metrics.
1
Information about "iNova Pharmaceuticals" in one article was determined to be for a different entity and thus not applicable to INO.US.
2
Respect for Cultures & Communities
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. The articles discuss Inovio's vaccine development process, partnerships with other pharmaceutical companies, and broader issues of genetic resource use and vaccine distribution disparities, but they do not contain concrete data points on formal partnerships with indigenous or local community groups, revenue reinvested locally, cultural appropriation incidents, cultural impact assessment protocols, local employment, grievance mechanisms, or other specified metrics for Inovio Pharmaceuticals, Inc.
Safe & Smart Tech
0
Inovio Pharmaceuticals, Inc.'s privacy policy states that information is collected only for stated purposes, indicating standard data minimization practices.
1
Users are able to unsubscribe from email newsletters, suggesting industry-standard user data control.
2
The company's 2018 Form 10-K mentions compliance with relevant regulations in the context of its operations, and its privacy policy references GDPR, indicating basic regulatory compliance.
3
No incidents of unauthorized data use are mentioned in the provided documents.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for Inovio Pharmaceuticals, Inc. (INO.US) regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
The articles primarily discuss corporate governance, financial reporting, general biotechnology business, or sustainability efforts of other companies/general industry trends, and explicitly state a lack of relevant data for INO.US in this area.
2